Diagnostic Liaison Oncology

Diagnostic Liaison - Oncology;

London and South East Region

22 October 2026

As a Diagnostic Liaison, you will accelerate appropriate testing and timely diagnosis by enabling high-quality, guideline-aligned histopathology, molecular and biomarker testing across solid tumour pathways. You will build strong partnerships across NHS and private laboratories, pathology services and clinical pathways to remove operational barriers, optimise test adoption, and support HCP decision-making aligned to AstraZeneca’s oncology portfolio and patient needs. This is a full-time, permanent position for the London and South East geography, including relevant Genomic Laboratory Hub, pathology network, Cancer Alliance and private provider ecosystems.

• Ecosystem engagement:
  Identify, map and develop strategic relationships across oncology diagnostic pathways for all relevant tumour types and biomarkers. Stakeholders will include cellular and molecular pathologists, histopathology laboratory managers, laboratory directors, Genomic Laboratory Hubs, pathology networks, digital pathology leads, MDT coordinators, oncologists, surgeons, radiologists, CNS/ANP teams, Cancer Alliances, ICBs, private hospital and laboratory groups, and diagnostic and technology companies.
• Pathway optimisation:
  Diagnose bottlenecks across the end-to-end diagnostic pathway, including tissue acquisition, fixation, processing, histopathology assessment, biomarker triage, test ordering, sample referral, analysis, reporting and clinical interpretation. Co-create tailored solutions such as reflex or parallel testing, improved tissue stewardship, digital pathology-enabled workflows, sample logistics, reporting turnaround improvements, interoperability and MDT integration to improve patient identification and time to treatment.
• Biomarker excellence:
  Drive awareness, quality and appropriate use of all priority and emerging biomarkers relevant to AstraZeneca’s oncology portfolio across tumour types. Support fit-for-purpose testing strategies spanning protein, DNA, RNA, genomic, immune, circulating and digital biomarkers, aligned with NICE, national guidance and recognised pathology standards.
• Education:
  
  Develop and deliver non-promotional, compliant educational programmes on histopathology and molecular testing standards, tissue and sample quality, assay selection and validation, digital pathology adoption, image analysis, reflex and parallel testing, quality assurance, interpretation and reporting best practice for relevant NHS and private-sector customer groups.
• Evidence and insights:
  Gather and synthesise field insights across NHS and private testing pathways, including access, capacity, turnaround times, failure rates, tissue insufficiency, biomarker testing uptake, reflex testing, digital pathology maturity, reporting quality and guideline adherence. Feed actionable insights back to cross-functional teams to inform portfolio, brand and diagnostic strategy.
• Cross-functional execution:
  Partner with Brand, Medical, Diagnostics, Market Access, and Key Account teams to design and execute regional tactical plans; monitor KPIs and outcomes (e.g., testing rates, TAT reduction, MDT adoption).
• Compliance:
  Adhere to AZ Code of Conduct, Standards, SOPs, ABPI/ABHI and local regulatory requirements for scientific interactions and materials.

Diagnostics Leader and Diagnostics team, Cross-Functional Brand Teams, Medical Affairs, Market Access, Key Account Management, Real-World Evidence/HEOR as applicable.

Cellular and molecular pathology experts, histopathology and laboratory leaders, Genomic Laboratory…